UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Harms in Systematic Reviews Paper 1: An introduction to research on harms

Journal of clinical epidemiology, 2022-03, Vol.143, p.186-196

2022

Link zum Volltext

Verfügbarkeit prüfen

Harms were detected but not reported in six clinical trials of gabapentin

Journal of clinical epidemiology, 2023-12, Vol.164, p.76-87

2023

Link zum Volltext

Verfügbarkeit prüfen

Summaries of harms in systematic reviews are unreliable Paper 1: An introduction to research on harms

Journal of clinical epidemiology, 2021-11, Vol.143, p.186-196

2021

Link zum Volltext

Verfügbarkeit prüfen

The Oxford Implementation Index: a new tool for incorporating implementation data into systematic reviews and meta-analyses

Journal of clinical epidemiology, 2013-08, Vol.66 (8), p.874-882

2013

Link zum Volltext

Verfügbarkeit prüfen

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Journal of clinical epidemiology, 2021-06, Vol.134, p.178-189

2021

Link zum Volltext

Verfügbarkeit prüfen

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy

Journal of clinical epidemiology, 2017-11, Vol.91, p.95-110

2017

Link zum Volltext

Verfügbarkeit prüfen

Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis

Journal of clinical epidemiology, 2017-06, Vol.86, p.39-50

2017

Link zum Volltext

Verfügbarkeit prüfen

Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms

Journal of clinical epidemiology, 2022-03, Vol.143, p.224-241

2022

Link zum Volltext

Verfügbarkeit prüfen

Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin

Journal of clinical epidemiology, 2022-03, Vol.143, p.212-223

2022

Link zum Volltext

Verfügbarkeit prüfen

Methodology reporting improved over time in 176,469 randomized controlled trials

Journal of clinical epidemiology, 2023-10, Vol.162, p.19-28

2023

Link zum Volltext

Verfügbarkeit prüfen

The selection of comparators for randomized controlled trials of health-related behavioral interventions: recommendations of an NIH expert panel

Journal of clinical epidemiology, 2019-06, Vol.110, p.74-81

2019

Link zum Volltext

Verfügbarkeit prüfen

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events

Journal of clinical epidemiology, 2019-09, Vol.113, p.11-19

2019

Link zum Volltext

Verfügbarkeit prüfen

Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events

Journal of clinical epidemiology, 2019-09, Vol.113, p.20-27

2019

Link zum Volltext

Verfügbarkeit prüfen

CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials

Journal of clinical epidemiology, 2023-06, Vol.158, p.149-165

2023

Link zum Volltext

Verfügbarkeit prüfen

Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations

Journal of clinical epidemiology, 2019-10, Vol.114, p.84-94

2019

Link zum Volltext

Verfügbarkeit prüfen

Improving the analysis of adverse event data in randomized controlled trials

Journal of clinical epidemiology, 2022-04, Vol.144, p.185-192

2022

Link zum Volltext

Verfügbarkeit prüfen

Recording harms in randomized controlled trials of behavior change interventions: a scoping review and map of the evidence

Journal of clinical epidemiology, 2024-05, Vol.169, p.111275-111275, Article 111275

2024

Link zum Volltext

Verfügbarkeit prüfen

Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements

Journal of clinical epidemiology, 2024-05, Vol.169, p.111309-111309, Article 111309

2024

Link zum Volltext

Verfügbarkeit prüfen

Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration

Journal of clinical epidemiology, 2016-02, Vol.70, p.68-89

2016

Link zum Volltext

Verfügbarkeit prüfen

Editorial Board

Journal of clinical epidemiology, 2024-04, Vol.168

2024

Link zum Volltext

Verfügbarkeit prüfen

Editorial Board

Journal of clinical epidemiology, 2024-03, Vol.167

2024

Link zum Volltext

Verfügbarkeit prüfen

Risk of bias assessments in systematic reviews and meta-analyses of behavioral interventions for substance use outcomes

Journal of clinical epidemiology, 2021-11, Vol.139, p.20-27

2021

Link zum Volltext

Verfügbarkeit prüfen

Editorial Board

Journal of clinical epidemiology, 2024-02, Vol.166

2024

Link zum Volltext

Verfügbarkeit prüfen

Editorial Board

Journal of clinical epidemiology, 2023-09, Vol.161, p.IFC

2023

Link zum Volltext

Verfügbarkeit prüfen

Editorial Board

Journal of clinical epidemiology, 2024-01, Vol.165

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Epidemiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Epidemiology
(17)
Health Care Sciences & Services
(17)
Life Sciences & Biomedicine
(17)
Public, Environmental & Occupational Health
(17)
Science & Technology
(17)
Clinical Trials
(14)
Meta-Analysis
(11)
Intervention
(9)
Systematic Review
(8)
Harms
(7)
Internal Medicine
(7)
Studies
(7)
Systematic Reviews
(7)
Adverse Events
(6)
Gabapentin
(6)
Bias
(5)
Gabapentin - Adverse Effects
(5)
Literature Reviews
(5)
Meta-Analysis As Topic
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Harms in Systematic Reviews Paper 1: An introduction to research on harms

Harms were detected but not reported in six clinical trials of gabapentin

Summaries of harms in systematic reviews are unreliable Paper 1: An introduction to research on harms

The Oxford Implementation Index: a new tool for incorporating implementation data into systematic reviews and meta-analyses

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy

Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis

Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms

Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin

Methodology reporting improved over time in 176,469 randomized controlled trials

The selection of comparators for randomized controlled trials of health-related behavioral interventions: recommendations of an NIH expert panel

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events

Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events

CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials

Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations

Improving the analysis of adverse event data in randomized controlled trials

Recording harms in randomized controlled trials of behavior change interventions: a scoping review and map of the evidence

Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements

Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration

Editorial Board

Editorial Board

Risk of bias assessments in systematic reviews and meta-analyses of behavioral interventions for substance use outcomes

Editorial Board

Editorial Board

Editorial Board

Aktive Filter

Suchergebnisse filtern